News -CureApp, Inc.

  Toward Dissemination of Digital Therapeutics CureApp and Teijin Pharma Sign Agreement for Joint Marketing and Sales of Prescription Digital Therapeutic App for Hypertension Teijin Pharma Limited (Headquarters: Chiyoda-ku, Tokyo, President: Masaki Taneda, hereinafter Teijin Pharma) and CureApp, Inc. ( Headquarters: Chuo-ku, Tokyo, President: Kohta Satake, hereinafter CureApp) have concluded a joint marketing and sales agreement (hereinafter, joint agreement) for the "Prescription Digital Therapeutic App for Hypertension" (hereinafter, CureApp HT) as of April 1st. Through this partnership, we aim to expand the use of CureApp HT, which supports the lifestyle modifications that are a prerequisite to any type of hypertension treatment. Further, through the distribution of digital therapeutics (DTx) *1 , the two companies aspire to address unmet medical needs. *1 Digital therapeutics: medical devices that have been approved by regulatory authorities for their therapeutic effects,

CureApp Inc. has ranked in the ” World's Best Digital Health Companies 2024” list   CureApp Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) is pleased to announce that it has been selected as one of the ”World's Best Digital Health Companies 2024”. About World’s Best Digital Health Companies 2024 T his is the first survey conducted jointly by U.S. weekly magazine Newsweek and data intelligence platform Statista to identify new services and technologies that are transforming the digital health market. The survey included nearly 400 companies from 35 countries worldwide. For more details, please visit: https://www.newsweek.com/rankings/worlds-best-digital-health-companies-2024 Comments by Kota Satake, CEO, CureApp The size of the digital health market has grown rapidly both domestically and internationally, more than we imagined when we founded CureApp 10 years ago. Many companies and research institutions are advancing research and development all over the world. We are ve